Factors impacting progression-free survival (PFS) as a predictor of overall survival (OS)

被引：1
|
作者：
Stewart, David J.
Bosse, Dominick
Hilton, John Frederick
Goss, Glenwood D.
Fung-Kee-Fung, Michael
Jonker, Derek J.
机构：
[1] Ottawa Hosp, Ottawa, ON, Canada
[2] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[3] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[4] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.6556
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6556
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The validity of progression-free survival (PFS) 2 as a surrogate endpoint for overall survival (OS) in randomized controlled trials (RCTs) of advanced solid tumors.
    Woodford, Rachel
    Zhou, Deborah
    Kok, Peey-Sei
    Lord, Sally
    Marschner, Ian
    Friedlander, Michael
    Lee, Chee Khoon
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Correlation of treatment effects on progression-free survival at 6 months (PFS-6) and overall survival (OS) in patients with newly diagnosed glioblastoma (GBM).
    Ye, X.
    Grossman, S. A.
    Desideri, S.
    Piantadosi, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study
    Andre, T.
    Berton-Rigaud, D.
    Curigliano, G.
    Sabatier, R.
    Tinker, A. V.
    Oaknin, A.
    De Braud, F. G. M.
    Ellard, S.
    Arkenau, H-T.
    Trigo Perez, J. M.
    Brown, J.
    Jewell, A.
    Pikiel, J.
    Mirza, M. R.
    Duan, T.
    Antony, G.
    Zildjian, S.
    Zografos, E.
    Veneris, J.
    Banerjee, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S799 - S800
  • [34] Calculators for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients
    Sjoquist, Katrin Marie
    Bokemeyer, Carsten
    Renfro, Lindsay A.
    Simes, John
    Tebbutt, Niall C.
    Clarke, Stephen John
    Adams, Richard
    Punt, Cornelis J. A.
    Van Cutsem, Eric
    Douillard, Jean-Yves
    Hecht, J. Randolph
    Heinemann, Volker
    Sougklakos, Ioannis
    Diaz-Rubio, Eduardo
    Porschen, Rainer
    Meyers, Jeffrey P.
    Gonsalves, Wilson I.
    Sargent, Daniel J.
    De Gramont, Aimery
    Zalcberg, John Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] The FLIPI2 SCORE Predicts PROGRESSION-FREE SURVIVAL (PFS) and OVERALL SURVIVAL (OS) IN AN INDEPENDENT SERIES of Follicular LYMPHOMA: A Single Institution EXPERIENCE
    Jose Terol, Maria
    Isabel Teruel, Ana
    Amat, Paula
    Elaluf, Danella
    Tormo, Mar
    Solano, Carlos
    BLOOD, 2010, 116 (21) : 1288 - 1289
  • [36] Progression-free survival (PFS) as a surrogate for overall survival (OS) in patients with advanced colorectal cancer: An analysis of 3159 patients randomized in 11 trials.
    Buyse, M
    Burzykowski, T
    Carroll, K
    Michiels, S
    Pignon, JP
    Piedbois, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 249S - 249S
  • [37] Surrogacy of progression-free survival (PFS) for overall survival (OS) in rectal cancer trials with preoperative therapy: Literature-based meta-analysis.
    Mizusawa, Junki
    Nakamura, Kenichi
    Kataoka, Kozo
    Eba, Junko
    Katayama, Hiroshi
    Shibata, Taro
    Fukuda, Haruhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [38] Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis
    Kataoka, K.
    Nakamura, K.
    Mizusawa, J.
    Kato, K.
    Eba, J.
    Katayama, H.
    Shibata, T.
    Fukuda, H.
    EJSO, 2017, 43 (10): : 1956 - 1961
  • [39] Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC).
    Sjoquist, Katrin Marie
    Lee, Chee
    Lord, Sally
    Chatfield, Mark D.
    Friedlander, Michael
    Simes, John
    Marschner, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] NCCTG 96-94-53: Clinical variables associated with overall survival (OS), progression-free survival (PFS), 6 month progression-free survival (PFS6), immediate progression (ImmProg), and response in patients enrolled in recurrent glioma clinical trials.
    Buckner, J. C.
    Ballman, K.
    Schaefer, P.
    Furth, A. F.
    Giannini, C.
    Scheithauer, B. W.
    Galanis, E.
    Jaeckle, K. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 63S - 63S
12345